ANIP Stock Analysis: ANI Pharmaceuticals | NASDAQ

Injectables, Softgel Capsules, Oral Solids, Topicals

Total Rating 47

Safety 80

Buy Signal -1.31

Drug Manufacturers - Specialty & Generic
Industry Rotation: -2.1

Market Cap: 1.67B
Avg Turnover: 23.1M

Risk 3d forecast

Volatility33.9%

VaR 5^th Pctl5.78%

VaR vs Median3.51%

Reward TTM

Sharpe Ratio-0.76

Rel. Str. IBD13.8

Rel. Str. Peer Group21.9 pctl

Character TTM

Beta0.001

Beta Downside-0.060

Hurst Exponent0.375

Choppyness61.5%

Drawdowns 3y

Max DD29.00%

CAGR/Max DD0.14

CAGR/Mean DD0.28

EPS (Earnings per Share)

EPS CAGR: 22.95%
EPS Trend: 60.2%

Last SUE: 0.33
Qual. Beats: 0

Revenue

Rev. CAGR: 34.49%
Rev. Trend: 99.4%

Last SUE: 0.77
Qual. Beats: 0

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +1.8% 20

Feb -4.5% 9

Mar -2.0% 17

Apr -0.9% 5

May -0.1% 7

Jun +5.0% 32

Jul -1.4% 8

Aug -2.8% 16

Sep -3.9% 11

Oct -0.3% 11

Nov +2.8% 14

Dec -3.0% 25

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ANIP ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a U.S.-based biopharmaceutical company that develops, manufactures, and markets both branded and generic prescription pharmaceutical products for domestic and international markets. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

The companys product portfolio spans multiple dosage forms and therapeutic categories, including injectables, softgel capsules, Cortrophin gel, ILUVIEN, and YUTIQ, as well as oral solid doses, semi-solids, liquids, topicals, controlled substances, and potent products. Its customer base includes national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers.

ANI operates within the pharmaceuticals sector, where companies commonly pursue a dual business model balancing higher-margin branded or specialty products with high-volume generic manufacturing to diversify revenue streams and mitigate risks such as pricing pressure and patent expirations. The inclusion of specialty products like Cortrophin gel, ILUVIEN, and YUTIQ positions ANI in the niche segment of rare disease and specialty pharmaceuticals, which typically command premium pricing relative to commodity generics.

Headlines to Watch Out For

Cortrophin gel sales drive branded pharmaceutical revenue growth
Generic injectables portfolio expands through new product launches
Acquisition pipeline targets specialty and rare disease therapeutics

Piotroski VR-10 (Strict) 7.5

Net Income: 105.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.85 > 1.0
NWC/Revenue: 55.38% < 20% (prev 48.94%; Δ 6.43% < -1%)
CFO/TA 0.13 > 3% & CFO 189.5m > Net Income 105.8m
Net Debt (234.6m) to EBITDA (255.8m): 0.92 < 3
Current Ratio: 2.91 > 1.5 & < 3
Outstanding Shares: last quarter (21.9m) vs 12m ago 7.91% < -2%
Gross Margin: 65.23% > 18% (prev 61.06%; Δ 4.17% > 0.5%)
Asset Turnover: 68.97% > 50% (prev 55.65%; Δ 13.32% > 0%)
Interest Coverage Ratio: 4.86 > 6 (EBIT TTM 170.0m / Interest Expense TTM 35.0m)

Altman Z'' 3.95

A: 0.36 (Total Current Assets 825.4m - Total Current Liabilities 283.7m) / Total Assets 1.49b
B: 0.02 (Retained Earnings 31.1m / Total Assets 1.49b)
C: 0.12 (EBIT TTM 170.0m / Avg Total Assets 1.42b)
D: 0.67 (Book Value of Equity 597.2m / Total Liabilities 896.9m)
Altman-Z'' = 3.95 = AA

Beneish M -3.05

DSRI: 0.93 (Receivables 274.5m/225.7m, Revenue 978.4m/747.4m)
GMI: 0.94 (GM 61.06% / 65.23%)
AQI: 0.79 (AQ_t 0.40 / AQ_t-1 0.51)
SGI: 1.31 (Revenue 978.4m / 747.4m)
TATA: -0.06 (NI 105.8m - CFO 189.5m) / TA 1.49b)
Beneish M = -3.05 (Cap -4..+1) = AA

What is the price of ANIP shares?

As of November 03, 2026, the stock is trading at USD 70.67 with a total of 514,714 shares traded. Over the past week, the price has changed by -2.66%, over one month by -2.09%, over three months by -11.73% and over the past year by -24.87%.

Current recommended Stop Loss: 68.00 (which is 3.8% or 1.3 ATR below the current price).

Is ANIP a buy, sell or hold?

ANI Pharmaceuticals has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy ANIP.

StrongBuy: 4
Buy: 3
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ANIP price?

Analysts Target Price	105.8	49.7%

ANI Pharmaceuticals (ANIP) - Fundamental Data Overview as of 27 October 2026

Market Cap USD = 1.67b (1.67b USD * 1.0 USD.USD)
P/E Trailing = 15.7143
P/E Forward = 7.2046
P/S = 1.7045
P/B = 2.7924
P/EG = 1.8006
Revenue TTM = 978.4m USD
EBIT TTM = 170.0m USD
EBITDA TTM = 255.8m USD
Long Term Debt = 589.2m USD (from longTermDebt, last quarter)
Short Term Debt = 21.3m USD (from shortTermDebt, last quarter)
Debt = 610.5m USD (corrected: LT Debt 589.2m + ST Debt 21.3m)
Net Debt = 234.6m USD (calculated: Debt 610.5m - CCE 375.9m)
Enterprise Value = 1.90b USD (1.67b + Debt 610.5m - CCE 375.9m)
Interest Coverage Ratio = 4.86 (Ebit TTM 170.0m / Interest Expense TTM 35.0m)
EV/FCF = 11.93x (Enterprise Value 1.90b / FCF TTM 159.4m)
FCF Yield = 8.38% (FCF TTM 159.4m / Enterprise Value 1.90b)
FCF Margin = 16.30% (FCF TTM 159.4m / Revenue TTM 978.4m)
Net Margin = 10.82% (Net Income TTM 105.8m / Revenue TTM 978.4m)
Gross Margin = 65.23% ((Revenue TTM 978.4m - Cost of Revenue TTM 340.2m) / Revenue TTM)
Gross Margin QoQ = 62.35% (prev 51.78%)
Tobins Q-Ratio = 1.27 (Enterprise Value 1.90b / Total Assets 1.49b)
Interest Expense / Debt = 5.73% (Interest Expense 35.0m / Debt 610.5m)
Taxrate = 24.04% (34.3m / 142.6m)
NOPAT = 129.1m (EBIT 170.0m * (1 - 24.04%))
Current Ratio = 2.91 (Total Current Assets 825.4m / Total Current Liabilities 283.7m)
Debt / Equity = 1.02 (Debt 610.5m / totalStockholderEquity, last quarter 597.2m)
Debt / EBITDA = 0.92 (Net Debt 234.6m / EBITDA 255.8m)
Debt / FCF = 1.47 (Net Debt 234.6m / FCF TTM 159.4m)
Total Stockholder Equity = 551.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.46% (Net Income 105.8m / Total Assets 1.49b)
RoE = 19.19% (Net Income TTM 105.8m / Total Stockholder Equity 551.5m)
RoCE = 14.91% (EBIT 170.0m / Capital Employed (Equity 551.5m + L.T.Debt 589.2m))
RoIC = 10.92% (NOPAT 129.1m / Invested Capital 1.18b)
WACC = 5.30% (E(1.67b)/V(2.28b) * Re(5.65%) + D(610.5m)/V(2.28b) * Rd(5.73%) * (1-Tc(0.24)))
Discount Rate = 5.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.44 | Cagr: 5.51%
[DCF] Terminal Value 77.97% ; FCFF base≈137.7m ; Y1≈157.9m ; Y5≈232.3m
[DCF] Fair Price = 142.0 (EV 3.50b - Net Debt 234.6m = Equity 3.26b / Shares 23.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 60.15 | EPS CAGR: 22.95% | SUE: 0.33 | # QB: 0
Revenue Correlation: 99.36 | Revenue CAGR: 34.49% | SUE: 0.77 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.18 | Chg30d=+0.74% | Revisions=+17% | Analysts=9
EPS current Year (2026-12-31): EPS=9.26 | Chg30d=-0.26% | Revisions=-17% | GrowthEPS=+17.4% | GrowthRev=+24.9%
EPS next Year (2027-12-31): EPS=10.13 | Chg30d=-3.42% | Revisions=-17% | GrowthEPS=+9.3% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: -8% (up=4, down=5)